Question 1

What is Moleculin Biotech?

Accepted Answer

Moleculin Biotech is a Company.

Question 2

How often does Moleculin Biotech appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Moleculin Biotech first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was Moleculin Biotech last mentioned in news?

Accepted Answer

Last active on May 29, 2026.

Question 5

What is Moleculin Biotech's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Moleculin Biotech in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Moleculin Biotech?

Accepted Answer

Moleculin Annamycin Cardiac Safety Data (May 21, 2026, 7 articles).

Question 8

How did the "Moleculin Annamycin Cardiac Safety Data" event impact Moleculin Biotech?

Accepted Answer

Moleculin Biotech announced positive cardiac safety data for its lead drug candidate, Annamycin, at the 2026 ASCO Annual Meeting, reinforcing its potential as a safer anthracycline therapy and strengthening the rationale for its ongoing MIRACLE Phase 2b/3 trial.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.